HARPOON THERAPEUTICS INC's ticker is HARP and the CUSIP is 41358P106. A total of 54 filers reported holding HARPOON THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $620 | -1.6% | 873 | +3.1% | 0.00% | – |
| Q1 2023 | $630 | +59.5% | 847 | +55.7% | 0.00% | – |
| Q4 2022 | $395 | -60.5% | 544 | -47.7% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 1,041 | -0.7% | 0.00% | – |
| Q2 2022 | $2,000 | -93.9% | 1,048 | -84.4% | 0.00% | – |
| Q1 2022 | $33,000 | -66.7% | 6,722 | -48.6% | 0.00% | – |
| Q4 2021 | $99,000 | +1314.3% | 13,087 | +1331.8% | 0.00% | – |
| Q3 2021 | $7,000 | -96.1% | 914 | -92.9% | 0.00% | – |
| Q2 2021 | $179,000 | +105.7% | 12,882 | +208.8% | 0.00% | – |
| Q1 2021 | $87,000 | -73.1% | 4,171 | -78.5% | 0.00% | – |
| Q4 2020 | $323,000 | -24.4% | 19,417 | -22.7% | 0.00% | – |
| Q3 2020 | $427,000 | +4.4% | 25,118 | +1.9% | 0.00% | – |
| Q2 2020 | $409,000 | +62.3% | 24,657 | +13.3% | 0.00% | – |
| Q1 2020 | $252,000 | +33.3% | 21,765 | +69.9% | 0.00% | – |
| Q4 2019 | $189,000 | +78.3% | 12,807 | +65.5% | 0.00% | – |
| Q3 2019 | $106,000 | +12.8% | 7,737 | +6.8% | 0.00% | – |
| Q2 2019 | $94,000 | – | 7,241 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 3,156,699 | $15,689,000 | 7.73% |
| MPM ASSET MANAGEMENT LLC | 3,131,388 | $15,563,000 | 5.32% |
| MPM BioImpact LLC | 3,196,707 | $15,888,000 | 4.26% |
| ACUTA CAPITAL PARTNERS, LLC | 497,500 | $2,473,000 | 1.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 151,445 | $2,771,000 | 0.62% |
| Orbimed Advisors | 3,039,508 | $15,106,000 | 0.24% |
| Artal Group S.A. | 1,000,000 | $4,970,000 | 0.21% |
| Cormorant Asset Management, LP | 540,600 | $2,687,000 | 0.21% |
| DAFNA Capital Management LLC | 105,163 | $523,000 | 0.14% |
| Ikarian Capital, LLC | 117,009 | $582,000 | 0.08% |